25752887|t|An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases.
25752887|a|Inflammation is involved in the pathophysiology of many chronic diseases, such as rheumatoid arthritis and neurodegenerative diseases. Several studies have evidenced important anti-inflammatory and immunomodulatory properties of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs). This review illustrates current knowledge about the efficacy of n-3 LC-PUFAs (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), particularly) in preventing and/or treating several chronic inflammatory conditions (inflammatory bowel diseases and rheumatoid arthritis) as well as their potential benefits on neurodegenerative diseases. It is well established that n-3 LC-PUFAs are substrates for synthesis of novel series of lipid mediators (e.g., resolvins, protectins, and maresins) with potent anti-inflammatory and pro-resolving properties, which have been proposed to partly mediate the protective and beneficial actions of n-3 LC-PUFAs. Here, we briefly summarize current knowledge from preclinical studies analyzing the actions of EPA- and DHA-derived resolvins and protectins on pathophysiological models of rheumatoid arthritis, Alzheimer, and irritable bowel syndrome. 
25752887	25	44	omega-3 fatty acids	Chemical	MESH:D015525
25752887	48	86	inflammatory and degenerative diseases	Disease	MESH:D019636
25752887	88	100	Inflammation	Disease	MESH:D007249
25752887	144	160	chronic diseases	Disease	MESH:D002908
25752887	170	190	rheumatoid arthritis	Disease	MESH:D001172
25752887	195	221	neurodegenerative diseases	Disease	MESH:D019636
25752887	269	281	inflammatory	Disease	MESH:D007249
25752887	317	363	omega-3 long-chain polyunsaturated fatty acids	Chemical	-
25752887	365	377	n-3 LC-PUFAs	Chemical	-
25752887	444	456	n-3 LC-PUFAs	Chemical	-
25752887	458	479	eicosapentaenoic acid	Chemical	MESH:D015118
25752887	481	484	EPA	Chemical	MESH:D015118
25752887	490	510	docosahexaenoic acid	Chemical	MESH:D004281
25752887	512	515	DHA	Chemical	MESH:D004281
25752887	578	601	inflammatory conditions	Disease	MESH:D007249
25752887	603	630	inflammatory bowel diseases	Disease	MESH:D015212
25752887	635	655	rheumatoid arthritis	Disease	MESH:D001172
25752887	696	722	neurodegenerative diseases	Disease	MESH:D019636
25752887	752	764	n-3 LC-PUFAs	Chemical	-
25752887	813	818	lipid	Chemical	MESH:D008055
25752887	836	845	resolvins	Chemical	-
25752887	863	871	maresins	Chemical	-
25752887	890	902	inflammatory	Disease	MESH:D007249
25752887	1017	1029	n-3 LC-PUFAs	Chemical	-
25752887	1126	1129	EPA	Chemical	MESH:D015118
25752887	1135	1138	DHA	Chemical	MESH:D004281
25752887	1147	1156	resolvins	Chemical	-
25752887	1204	1224	rheumatoid arthritis	Disease	MESH:D001172
25752887	1226	1235	Alzheimer	Disease	MESH:D000544
25752887	1241	1265	irritable bowel syndrome	Disease	MESH:D043183
25752887	Negative_Correlation	MESH:D015118	MESH:D019636
25752887	Negative_Correlation	MESH:D004281	MESH:D007249
25752887	Negative_Correlation	MESH:D004281	MESH:D000544
25752887	Negative_Correlation	MESH:D015118	MESH:D007249
25752887	Association	MESH:D015525	MESH:D019636
25752887	Negative_Correlation	MESH:D015118	MESH:D000544
25752887	Negative_Correlation	MESH:D015118	MESH:D001172
25752887	Negative_Correlation	MESH:D004281	MESH:D043183
25752887	Negative_Correlation	MESH:D004281	MESH:D019636
25752887	Negative_Correlation	MESH:D015118	MESH:D015212
25752887	Negative_Correlation	MESH:D015118	MESH:D043183
25752887	Negative_Correlation	MESH:D004281	MESH:D015212
25752887	Negative_Correlation	MESH:D004281	MESH:D001172

